SanFerin®-protects naturally and supports the immune system in case of infections
An intact immune system is the body's defense against infections. The human body is exposed daily to viruses, bacteria and fungi and is attacked by pathogens. Stress, unhealthy diet and too little exercise at fresh air can weaken the immune system. When the immune system is not intact, pathogens can invade the body and infections can be the result.
Respiratory tract infections and urinary tract infections are often the result of a weakened immune system. With Lysozyme and Lactoferrin, SanFerin® supports the body's own defense and strengthens your immune system in the fight against pathogens. The natural ingredients in SanFerin® are safe, free from side effects and help to strengthen your body's defenses. SanFerin® neither has a negative influence on the intestinal flora, nor do pathogens become resistant to SanFerin® even after long-term use.
When is it recommended to take SanFerin®?
Based on this composition, SanFerin® tablets can be used as a dietary supplement by persons who benefit from the controlled intake of lactoferrin and lysozyme.
When can SanFerin® be recommended?
- for uncomplicated infections of the upper and lower respiratory tract
- for uncomplicated infections in the urogenital area
- or milder gastro-intestinal infections
- for uncomplicated skin infections
- for taking together with antibiotic therapy
1 tablet SanFerin® contains:
- Lactoferrin 50 mg
- Lysozyme 20 mg
- Green tea extract*) 100 mg
- Mannose 150 mg
- Zinc 2 mg
*) includes epigallocatechine-gallate (EGCG)
Dietary food supplement available in pharmacies!
Free of lactose, gluten, sugar and artificial colours.
How should SanFerin® be taken?
Adults and children over the age of 10:
For the first two days, take: 2 x 3 tablets (6 tablets) per day,
then: 2 x 2 tablets (4 tablets) per day
Children between the age of 6 and 10
For the first two days, take: 2 x 2 tablets (4 tablets) per day,
then 2 x 1 tablet (2 tablets) per day.
Take the tablets with plenty of liquid before or together with a meal.
SanFerin® can be taken over a longer period of time (several months)
When can SanFerin® not be recommended?
SanFerin® tablets are generally well tolerated. It cannot be recommended for persons with a chicken egg allergy because lysozyme is made of chicken eggs. Therefore, children between the ages of 6 and 10, in whom an allergy to hen eggs cannot be conclusively excluded, should not take SanFerin® tablets.
Before you take SanFerin® tablets together with an antibiotic, consult your physician.
Active ingredients of SanFerin®
Lactoferrin is a protein which binds a significant quantity of iron. It occurs in the entire organism and is responsible for many tasks. Its function can be changed by the pH-value and the extent of iron saturation. Most pathogenic bacteria require iron for growth. The antibacterial effect of lactoferrin comes in part from lactoferrin withdrawing iron and therefore, acting as a bacterial growth inhibitor.
Lactoferrin is an integral part of the first line of defence against pathogens at many entry points of the body. It is in most, if not all body fluids including blood, urine, perspiration, tears, saliva, gastric juices, intestinal secretion, vaginal secretion and nasal secretion. Lactoferrin is found in high concentrations in breast milk, this protects the infant effectively against enteral infections during the very first stage of life. Lactoferrin is mainly formed in neutrophilic granulocytes, which release lactoferrin together with other peptides of the immune system. Many types of cells in the body have receptors for lactoferrin.
There have been a large number of scientific research studies conducted on the antibacterial, antiviral, antimycotic and even with antiparasitic characteristics of lactoferrin. Among them are comparison studies of human and bovine forms, which demonstrate that both are essentially bioequivalent in function. Lactoferrin has an antibacterial effect on gram-positive and gram-negative bacteria by various modes of action. It can inhibit pathogens from entering tissue cells. It can bind to the membrane of pathogenic microbes and interfere with their formation of the membrane. These damages in the membrane make pathogens susceptible to other antimicrobial actions such as antibiotics, bacteriophages, lysozyme or other microorganisms. Lactoferrin is also capable of penetrating the pathogens. By binding to and/or hydrolysis of both DNA and RNA, they can inhibit their function and development from the inside. For some types of bacterial pathogens, such inhibition either in vitro and/or in vivo is documented. Among them are E. coli, Streptococcus, Staphylococcus, Listeria, Clostridia (e.g. Clostridium difficile), Shigella, Helicobacter, etc.
Development of biofilms
Biofilms are microbial symbioses that continuously change. They can consist of a single type of bacteria or fungus or which is more often the case, they can be polymicrobial, i.e. they consist of several different types of microorganisms.
Phase 1: Surface adhesion of microorganisms: The initial adhesion
Phase 2: Permanent surface adhesion: While bacteria multiply, they adhere more firmly to the surface. This is the beginning of mucous formation.
Phase 3: Formation of mucilaginous protective matrix/biofilm: Secretion of enveloping matrix substances as protective "slime" and spore formation.
Phase 4: "Maturation" of the biofilm: Parts of the biofilm detach and bacteria/spores leave the matrix.
Clinical studies on the supplementation of lactoferrin prove the effectiveness of lactoferrin in dissolving biofilms and in reducing infections caused by Helicobacter pylori or Clostridium difficile. The effect lactoferrin has on biofilms can improve the effectiveness of antibiotics on the eradication of pathogenic microbes, which could be shown in studies. Lactoferrin improves the effect of various antibiotics against gram-negative bacteria.
Lactoferrin is also capable of inhibiting pathogens indirectly in the intestine thereby improving the living conditions of non-pathogenic, probiotic lactobacilli and Bifidobacterium. These probiotic microbes are adapted to low iron demand and by lactoferrin capturing iron, it helps to maintain the low iron concentration in the intestine. Therefore, lactoferrin also shows a prebiotic effect.
Virus inhibiting properties by Lactoferrin are caused by its binding to the surface of tissue cells, in which viruses aim for proliferation. This effect reduces the penetration of viruses into these cells by reducing or preventing their replication. In addition, lactoferrin can bind to viral coat proteins as well, thereby blocking the defence of viruses. It can penetrate viruses and hydrolyse proteolytically their RNA. This deactivates the function of the virus. Antiviral properties were proven for both the human and the bovine lactoferrin. There were no significant differences found in their biological functions. Viruses sensitive to the inhibition by lactoferrin are Herpes simplex, all important subtypes of Influenza, Hepatitis C, Adenoviruses, the SARS virus and Cytomegaly viruses but also HIV.
The antimycotic properties of these proteins are revealed in the inhibition of numerous strains of Candida. Moreover, both forms are antiparasitically active against some Protozoa such as Toxoplasmas.
In addition to its effect on living pathogens, lactoferrin has detoxifying properties because of binding sites for endotoxins and an enzyme activity, which support the removal of toxins. These properties of lactoferrin protect from damage by toxins and they help the body to deal with bacterial toxins. It also has anti-oxidative and anti-inflammatory properties, which further protect the body from the effects of released toxins and from chronic inflammatory processes by inhibiting the pro-inflammatory cytokines of mastocytes. This slows down the inflammation cascade and modulates it. Lactoferrin can also have an anti-oxidative effect and therefore, reduce oxidative stress in the body.
It is interesting that low concentrations of lactoferrin are found in chronic diseases. With increasing age, the plasma level of lactoferrin decreases. In addition, neutrophilic granulocytes in diabetic patients show a lower lactoferrin level compared to non-diabetics. All these facts gave rise to the assumption that lower circulated lactoferrin plays a role in insulin resistance through low-grade, chronic inflammations.
Other studies with lactoferrin in humans show application options beyond pathogens and parasites. It could be shown that the skin lipid concentration was lower after taking lactoferrin orally. The skin lipid concentration is an important factor in the manifestation of acne.
In vitro and animal studies point toward additional areas of indications for lactoferrin such as protection from osteoporosis through the activation of osteoblasts while simultaneously inhibiting osteoclasts; the protection of the cartilage through the activation of chondrocytes; the influence on the lipid and blood glucose metabolism; maintaining a healthy urinary tract and healthy airways; the vaginal area; the liver; stomach; to support wound healing and shortening convalescence.
The application of lactoferrin aims particularly to protect the airways from mixed bacterial-viral infections such as colds, bronchitis, tonsillitis, otitis, sinusitis, pharyngitis, and laryngitis and at preventing intestinal infections as well as urogenital infections. Furthermore, it acts against acne through an antibacterial and metabolic activity of this versatile protein.
The lactoferrin in SanFerin® is made of cow’s milk.
Lysozyme, the antibacterial effect of lysozyme was discovered by Sir Alexander Fleming in 1922, when he noticed that the nasal mucus of a patient with a head cold inhibited the growth of bacteria on an agar plate. Since then, lysozyme has become one of the best-investigated proteins. It was the first enzyme, where the x-ray crystalline structure was determined.
Lysozyme is a glycosidase enzyme also known as muramidase because it can dissolve the murein layer of bacteria. It destroys the cell wall and the bacterium dies. These breakdown products of the bacterial wall generated by lysozyme support the macrophages to initiate the immune response.
Lysozyme is produced not only in haematopoietic cells such as granulocytes, monocytes and macrophages but also in epithelial cells of the respiratory tract and the epithelial cells of the salivary glands. Lysozyme is found in bodily fluids such as tears, saliva, blood and in breast milk. The normal plasma concentration is between 4-13 mg/L. It belongs to the first line of defence against bacteria because of its muramidase activity. Lysozyme is found everywhere in nature. It occurs in mammals, reptiles, insects, and plants. It is in the milk of animals and in the colostrum. In humans, lysozyme is found in bodily fluids such as saliva, earwax, tears, in the cerebrospinal fluid, in blood, in the amniotic fluid, in secretions of the mucus membranes of the respiratory tract, the cervix and the intestines, in the skin and in urine as well as in the granulocytes of neutrophils and the macrophages. Lysozyme combined with lactoferrin can also be found in breast milk.
In humans and animals, lysozyme serves as a barrier on the skin, in the eyes, in the intestine and the airways against pathogenic bacteria entering and proliferating, as well as against some viruses and fungi. This applies to gram-positive bacteria. Lysozyme also has an effect against gram-negative bacteria; however, these bacteria have an additional outer membrane composed of lipopolysaccharides. This membrane can be penetrated by lactoferrin and/or defensins, which creates a synergism between lactoferrin and lysozyme. The synergistic effect of these two substances was first demonstrated in 1991.
The effect lysozyme has on various strains of probiotic Bifidobacterium has also been investigated. These probiotic bacteria reacted to lysozyme less intensively if these were from humans compared to strains isolated from animals despite the fact that both were the same type of bacteria. This means that probiotic bacteria have arranged themselves with lysozyme and together they can even attack pathogenic bacterial strains.
In addition, lysozyme acts against some fungal infections such as infections caused by Aspergillus types, Candida types such as Candida albicans and Candida parapsilosis. In addition, lysozyme acts against viruses. It was found that persons treated with lysozyme before blood transfusions were less likely to suffer from hepatitis.
In addition to their individual antimicrobial mechanisms, lactoferrin and lysozyme show synergistic antibacterial characteristics against a series of gram-negative bacteria, which is likely caused by lactoferrin's effect of making the outer membrane more permeable and therefore, allowing lysozyme to enter the bacterium. Lactoferrin and lysozyme are the most important ingredients in breast milk. They have been getting more and more attention because of their gentle but high-performance mode of action in preventing infections. These substances in breast milk protect the newborn against diarrhoea, infections of the respiratory tract, meningitis and other infectious diseases.
The lysozyme in SanFerin® is derived from chicken eggs.
In SanFerin®, lysozyme combined with lactoferrin acts effectively against bacteria, viruses, fungi or parasites entering or multiplying and it promotes the reduction of biofilms and therefore, it increases the effectiveness of antimicrobial substances.
Green tea extract (EGCG)
Green tea (Camellia sinensis) is worldwide a popular beverage. It has been linked to health benefits for a long time. Compared with other teas, the composition of green tea extract has been reasonably researched and therefore, it is better known.
There are numerous published studies on the chemo-preventive effect green tea has on cancer. This effect of green tea is based on its polyphenols known as catechins.
The most important catechin in green tea is EGCG (epigallocatechin-3-gallate), which makes up 50% to 80% of the green tea extract or 200 to 300 mg per cup of tea. EGCG even has other health benefits. It has an anti-oxidative effect. It is often discussed as substance protection from Alzheimer's disease and it is said to protect against arteriosclerosis, stroke and obesity. As a known antioxidant, EGCG counteracts inflammatory processes. Green tea polyphenols also inhibit cell proliferation. Experimental studies suggest this polyphenol inhibits tumour growth by inhibiting the angiogenesis and metastasis.
Bacterial/viral infections always induce inflammatory processes as reaction of the immune system. Therefore, EGCG combined with antimicrobial substances can play an important role as an inflammation suppressing agent with regard to symptoms of the disease.
D-mannose is found in the human metabolism. It plays an important role particularly in the glycosylation of certain proteins. The antibacterial mode of action is based on the inhibition of the bacterial adhesion to uroepithelial cells, particularly the adhesion of E. coli, a primary pathogen in urinary tract infections. In vitro experiments have shown that
D-mannose binds to the fimbriae of uropathogenic microbes thereby blocking FimH adhesin, which is positioned on the tip of the type 1 fimbriae of enteral bacteria. During a bacterial colonization, FimH binds to the carbohydrate (mannose) of the glycoprotein receptors of the uroepithelium. D-mannose acts as competitive inhibitor of the bacterial adherence. If sufficiently concentrated in urine, D-mannose saturates the FimH adhesin and prevents bacteria from binding to urothelial receptors. If bacteria are unable to dock onto urothelial structures, they are washed out with the urine and they cannot develop their pathogenic potency. Consequentially, the bacteriuria is reduced.
Mannose in SanFerin® prevents the adhesion of uropathogenic microbes /such as E. coli). Therefore, it can be used as prophylactic or treatment of existing urinary tract infections.
The mannose in SanFerin® is derived from birch trees and beech wood.